Alcohol-Induced Liver Decompensation Treatment Study
ELAD is an investigational human liver cell-based treatment designed to improve survival of subjects with liver failure by providing liver support continuously for up to five days. This study specifically focuses on individuals with alcohol-induced liver decompensation (AILD). Overall, 150 patients will be recruited for this study. At Rush University Medical Center, we expect to enroll 5 patients. The treatment will be assigned randomly.
In order to participate you must meet the following criteria:
- Be 18-49 years old.
- Be diagnosed with acute alcoholic hepatitis.
- Have a bilirubin greater than or equal to 16 mg/dL.
You will be excluded from the study if any of the following criteria apply to you:
- Are on dialysis.
- Have liver disease related to homozygous hemachromotosis, Wilson’s Disease, have non-alcoholic fatty liver disease, or Budd-Chiari Syndrome.
- Are unable to provide an address for follow-up home health visits.
This is a partial list of elgibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.